1.Eskander RN, Sill MW, Beffa L, et al. SEMINAL: Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: the phase 3, NRG GY018 study. 2023 Annual Global Meeting of theInternationalGynecologic Cancer So...
根据NRG GY018试验的结果,在不考虑PD-L1表达情况的子宫内膜癌患者中,与单独化疗相比,卡铂+紫杉醇(CP)化疗加用帕博利珠单抗显著改善了无进展生存期(PFS)。在2024 SGO会议上,加州大学圣地亚哥分校摩尔斯癌症中心Ramez N. Eskander也介绍了NR...
根据NRG GY018试验的结果,在不考虑PD-L1表达情况的子宫内膜癌患者中,与单独化疗相比,卡铂+紫杉醇(CP)化疗加用帕博利珠单抗显著改善了无进展生存期(PFS)。在2024 SGO会议上,加州大学圣地亚哥分校摩尔斯癌症中心Ramez N. Eskander也介绍了NRG GY018试验未成熟的总生存(OS)结果,即在错配修复(MMR)缺陷(dMMR)和MMR正...
根据NRG GY018试验的结果,在不考虑PD-L1表达情况的子宫内膜癌患者中,与单独化疗相比,卡铂+紫杉醇(CP)化疗加用帕博利珠单抗显著改善了无进展生存期(PFS)。在2024 SGO会议上,加州大学圣地亚哥分校摩尔斯癌症中心Ramez N. Eskander也介绍了NRG GY018试验未成熟的总生存(OS)结果,即在错配修复(MMR)缺陷(dMMR)和MMR正...
Video July 27, 2023 NRG-GY018 and RUBY Trials in Endometrial Cancer Author(s): Ritu Salani, MD,Ursula A. Matulonis, MD+3 MoreExperts on endometrial cancer review the NRG-GY018 and RUBY clinical trials. Video Player is loading. This is a modal window. This video is either unavailable or...
Bhavana Pothuri, MD, discusses the promise of the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.